Molecular structure of LDN-214117, CAS Number: 1627503-67-6
LDN-214117 (CAS 1627503-67-6)
Alternate Names:
1-[4-[6-methyl-5-(3,4,5-trimethoxyphenyl)-3-pyridinyl]phenyl]-piperazine
CAS Number:
1627503-67-6
Molecular Weight:
419.5
Molecular Formula:
C25H29N3O3
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
LDN-214117 (CAS 1627503-67-6) References
- Structure-activity relationship of 3,5-diaryl-2-aminopyridine ALK2 inhibitors reveals unaltered binding affinity for fibrodysplasia ossificans progressiva causing mutants. | Mohedas, AH., et al. 2014. J Med Chem. 57: 7900-15. PMID: 25101911
- Development of New Therapeutic Agents for Fibrodysplasia Ossificans Progressiva. | Luo, Y., et al. 2016. Curr Mol Med. 16: 4-11. PMID: 26695699
- Structural basis for the potent and selective binding of LDN-212854 to the BMP receptor kinase ALK2. | Williams, E. and Bullock, AN. 2018. Bone. 109: 251-258. PMID: 28918311
- Pharmacologic Strategies for Assaying BMP Signaling Function. | Dinter, T., et al. 2019. Methods Mol Biol. 1891: 221-233. PMID: 30414136
- ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. | Carvalho, D., et al. 2019. Commun Biol. 2: 156. PMID: 31098401
- Inhibition of bone morphogenetic protein signaling reduces viability, growth and migratory potential of non-small cell lung carcinoma cells. | Mihajlović, J., et al. 2019. J Cancer Res Clin Oncol. 145: 2675-2687. PMID: 31531741
- Targeting ALK2: An Open Science Approach to Developing Therapeutics for the Treatment of Diffuse Intrinsic Pontine Glioma. | Ensan, D., et al. 2020. J Med Chem. 63: 4978-4996. PMID: 32369358
- Leveraging an Open Science Drug Discovery Model to Develop CNS-Penetrant ALK2 Inhibitors for the Treatment of Diffuse Intrinsic Pontine Glioma. | Smil, D., et al. 2020. J Med Chem. 63: 10061-10085. PMID: 32787083
- Identification of an ALK-2 inhibitor as an agonist for intercellular exchange and tumor delivery of nanomaterial. | Wu, X., et al. 2023. Adv Ther (Weinh). 6: PMID: 36818419
- LC3 Accelerated Brain-Lung Axis Abscopal Effects after Fractionated Whole-Brain Radiation by Promoting Motoneurons to Secrete Periostin. | Zhang, K., et al. 2023. Radiat Res. 200: 462-473. PMID: 37796808
Inhibitor of:
ACRV1, ACTR-IA, ACTR-IB, ACTR-IIA, BMP-3, BMP-4, BMP-5, BMP-6, BMP-8B, BMP-9, BMP2, BMP2K, BMP2KL, BMP4, BMPR-IA, BMPR-II, Dlx-5, Evx-2, GDF-10, GDF-3, GDF-5, GDF5OS, gremlin-1, GSC2, IL-3Rβ, LRP4, LRRC72, MIXL1, NOMO1, NOMO3, RNF175, SCUBE2, Smad1, Smad5, Smad8, TBX22, WFIKKN, and ZIP-kinase.Activator of:
ACTR-IIA, BMP2, BMP4, brachyury 2, cerberus, dpp, EG546325, GDF-11, gremlin-2, Inhibin β-B, Nkx-2.2, RGMb, Smad6, and TLE2.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
LDN-214117, 5 mg | sc-507451 | 5 mg | $165.00 |